share_log

Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

阿亚拉制药(纳斯达克股票代码:ADXS)的研究报道始于 StockNews.com
Financial News Live ·  2023/03/24 04:44

Equities research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Thursday. The firm set a "sell" rating on the stock.

StockNews.com的股票研究分析师假设对以下股票进行了报道 阿亚拉制药(纳斯达克股票代码:ADXS — 获取评级) 在周四发布的一份报告中。该公司对该股设定了 “卖出” 评级。

Ayala Pharmaceuticals Stock Performance

阿亚拉制药股票表现

Shares of ADXS traded up $0.14 on Thursday, reaching $1.50. The stock had a trading volume of 3,325 shares, compared to its average volume of 7,793. Ayala Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $10.71.

周四,ADXS的股价上涨了0.14美元,达到1.50美元。该股的交易量为3,325股,而平均交易量为7,793股。阿亚拉制药创下12个月低点1.00美元,12个月高点为10.71美元。

Get
获取
Ayala Pharmaceuticals
阿亚拉制药
alerts:
警报:

About Ayala Pharmaceuticals

关于阿亚拉制药

(Get Rating)

(获取评级)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Advaxis, Inc是一家生物技术公司,从事癌症免疫疗法的发现、开发和商业化。它管理的平台技术利用活的减毒单核细胞增生李斯特菌分泌抗原或辅助融合蛋白。该公司拥有四个处于不同临床和临床前开发阶段的特许经营权,即:人乳头瘤病毒相关癌症、前列腺癌、新抗原疗法和热点突变疗法。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
  • KB Home Strong Results Lift Prices
  • Chewy Stock Is Setting Up For Long-Term Profitable Growth
  • Why Wall Street Loves These 3 Penny Stocks
  • Carvana May Be Able To Reach Profitability This Year
  • Low Volume Bunge Plunge Presents an Opportunity
  • 免费获取 StockNews.com 关于阿亚拉制药(ADXS)的研究报告的副本
  • KB Home 强劲业绩提振了价格
  • Chewy Stock 正在为长期盈利增长做准备
  • 为什么华尔街喜欢这三只细价股
  • Carvana 今年可能能够实现盈利
  • 低音量蹦极跳提供了机会

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收《阿亚拉制药日报》的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Ayala Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发